$FBCD Company News Move over HSN 12:04 p.m. March 27,

A Battle Over the Truth: Gildan's Legal Troubles Alright, buckle up, folks—it's time to dig deep into the gritty side of investing, where the glossy annual reports meet cold, hard skepticism. Gildan Activewear Inc., or GIL on the NYSE if you're still keeping track, has managed to embroil itself in some legal stews that even a seasoned trader like me can't ignore. Let's...

Picture this: You’re a big fish like Labcorp ready to feast on smaller catches. That’s exactly what’s rolling out as OPKO Health cuts a deal to offload a chunk of its BioReference Health assets to Labcorp for a tidy $722 million in cash. Assets on the Move OPKO’s BioReference Health has long been a player in the clinical testing world, with a focus on services...

Pushing the Limits with HYPERX Knit Look, healthcare workers ain't just clocking in and out—they're on their feet all day, twisting, reaching, and moving. So when HYPOTHESIS tossed this shin-dig in Los Angeles for their HYPERX knit collection, it wasn't just to show off some snazzy scrubs. It was about bridging a gap: wellness meets grind. You reckon a pair of old...

A New Milestone in Global Debate The Brewer Foundation is making waves across the debate world, claiming a groundbreaking enrollment for their 2026-27 International Public Policy Forum (IPPF). Let’s talk numbers for a moment—506 teams from a whopping 62 different countries, not to mention new entries from places like France, Mexico, Curaçao, and Russia, all eager to...

Strategic Moves in Biotech: The EQT-Qiagen Deal EQT Private Equity's latest maneuver has seasoned investors raising an eyebrow. They've just put an all-cash public takeover offer on the table for Qiagen, and no, this isn't your run-of-the-mill acquisition—it's a play steeped in strategy and capital dynamics. EQT's Portfolio Puzzle: Where Does Qiagen Fit? Let's break it...

Pearson's Q3 Performance: Crunch Time Checking the rearview mirror at Pearson's nine-month journey into 2026, it's quite the sight. Q3 revved up with a 6% growth spurt, aligning neatly with market expectations. Ain't that a relief in today's rocky terrain of education and assessment? Holding a tight rein, they're on course to meet the mid-single digit revenue growth they...

Essity's Balance Act in Q3: A Close Examination No looking through rose-tinted glasses here—Essity navigated the third quarter of 2026 with mixed indicators. Despite the broad strokes of stability, there's plenty beneath the surface worth a seasoned investor's eye. The company's net sales inched up by 4.1% to SEK 36,060 million. A nice figure, sure, but if you peek...

A New Face at the Helm of AEIC If you’ve been keeping tabs on the utility sector, then the recent shuffling of chairs over at the Association of Edison Illuminating Companies (AEIC) might have caught your eye. They just wrapped up their 142nd Annual Meeting in Ojai, where Ben Felton from Portland General Electric stepped into the limelight as the incoming President for...

Why Cognizant's Move Matters Imagine being at the top of your game, only to realize you need more heavy-hitters to keep your edge. That’s this deal in a nutshell. Cognizant (NASDAQ: CTSH) is diving deep into AI-led enterprise transformation by scooping up DyFlex Solutions, a name with plenty of clout in the SAP ecosystem. What's Behind the DyFlex Acquisition? Founded in...

Flu Season Isn't Just Sniffles: Accordia Health Speaks Up Listen up folks, it’s that time again and no, it ain’t just about digging out last year's scarf. Flu season is rolling in faster than a train outta hell, and already folks are talking about flu cases creeping up during the summer sunshine. We got Dr. Cameron Kilpatrick over at Accordia Health ringing the bell...

Celmatix Therapeutics Announces New Drug Program Celmatix Therapeutics, a biotechnology company dedicated to women's health, has recently launched an ambitious drug program focusing on a novel Jun-N-terminal kinase (JNK) inhibitor. This innovative therapeutic drug candidate is designed to effectively target pain and inflammation associated with various female health...

Accelera's Role in Green Hydrogen Production Accelera by Cummins, recognized for its commitment to zero-emissions solutions, is set to revolutionize the green hydrogen landscape with a groundbreaking 100-megawatt (MW) proton exchange membrane (PEM) electrolyzer system. This development, aimed at enhancing renewable energy projects, will play an instrumental role in bp's...

Curinos Amplero's Award-Winning AI Solution Recently, Curinos, a leading data intelligence firm in the financial sector, achieved prestigious recognition at the MarCom Awards for its innovative AI-powered platform, Amplero Personalization Optimizer. This platform, celebrated for its generative AI capabilities, played a vital role in the Private Wealth Cross-Sell Campaign...

Florida Housing Market Trends Overview As we dive into the current state of Florida's housing market, it's clear that exciting developments are taking place. In September, the sales of existing single-family homes experienced a robust increase of 13.6% compared to the previous year. Similarly, the sales of existing condo-townhouse units rose by 8% within the same...

Oakio Concludes Successful Participation at Batimat 2024 Oakio has successfully concluded its participation in Batimat 2024, a notable event held recently. This exhibition provided an excellent platform for showcasing a wide array of innovative Wood-Plastic Composite (WPC) solutions while connecting with industry professionals from around the world. Highlighting...